Athersys

OverviewSuggest Edit

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases.  The Company is engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of the proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

TypePublic
Founded1995
HQCleveland, USMap
Websiteathersys.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)83(+11%)
Revenue (FY, 2019)$5.6 M(-76%)
Share Price (Aug 2020)$2.6
Cybersecurity ratingAMore

Key People/Management at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Chairman & CEO
William Lehmann

William Lehmann

President, COO
John Harrington

John Harrington

Executive Vice President and Chief Scientific Officer
Laura Campbell

Laura Campbell

Controller
Manal Morsy

Manal Morsy

Vice President, Global Regulatory Affairs
Show more

Athersys Office Locations

Athersys has offices in Cleveland and Canton
Cleveland, US (HQ)
3201 Carnegie Ave
Canton, US
250 Royall St
Show all (2)

Athersys Financials and Metrics

Athersys Revenue

Athersys's revenue was reported to be $5.63 m in FY, 2019
USD

Net income (Q1, 2020)

(15.6m)

EBIT (Q1, 2020)

(15.8m)

Market capitalization (6-Aug-2020)

511.6m

Closing stock price (6-Aug-2020)

2.6

Cash (31-Mar-2020)

32.7m
Athersys's current market capitalization is $511.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.3m8.7m2.4m1.6m11.9m17.3m3.7m24.3m5.6m

Revenue growth, %

(33%)636%45%

General and administrative expense

4.9m4.8m6.1m6.9m7.5m7.8m8.5m10.4m11.4m

R&D expense

18.9m19.6m20.5m23.4m21.3m24.8m27.8m38.7m39.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

2.4m2.4m2.7m2.7m1.0m326.0k571.0k621.0k707.0k388.0k293.0k731.0k216.0k396.0k15.5m595.0k311.0k1.5m669.0k399.0k1.1m19.4m2.3m1.4m4.3m(361.0k)

General and administrative expense

1.4m1.1m1.3m1.2m1.1m1.5m1.6m1.5m1.8m1.8m1.7m1.9m1.9m1.9m2.0m2.0m1.8m2.1m2.2m2.1m2.7m2.4m2.6m3.1m2.9m3.0m3.5m

R&D expense

4.4m4.3m5.6m5.0m4.1m5.6m5.1m4.7m6.2m5.8m5.8m5.7m5.3m5.1m6.7m5.8m5.3m5.6m4.6m5.4m8.9m10.1m9.5m11.4m11.1m8.9m12.1m

Operating expense total

5.8m5.4m6.8m6.2m5.2m7.1m6.7m6.1m8.0m7.6m7.5m7.6m7.2m7.0m8.7m7.8m7.1m7.7m6.8m7.6m11.5m12.5m12.1m14.5m14.0m11.8m15.6m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

8.8m25.5m31.9m26.1m23.0m14.8m29.3m51.1m35.0m

Accounts Receivable

689.0k490.0k520.0k694.0k361.0k598.0k739.0k262.0k

Prepaid Expenses

304.0k286.0k387.0k427.0k429.0k1.1m1.8m1.2m

Current Assets

14.4m26.3m32.9m27.2m23.8m16.3m31.2m57.8m37.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

4.7m8.5m14.8m10.9m7.9m21.3m18.9m17.8m45.0m38.8m32.4m35.5m32.3m28.5m30.4m13.8m8.3m31.9m28.6m28.2m49.7m53.4m48.0m51.0m44.2m40.4m32.7m

Accounts Receivable

426.0k177.0k399.0k704.0k438.0k473.0k576.0k453.0k894.0k715.0k665.0k2.8m2.4m315.0k706.0k648.0k298.0k1.8m608.0k707.0k759.0k545.0k573.0k

Prepaid Expenses

341.0k636.0k256.0k305.0k370.0k293.0k328.0k283.0k319.0k310.0k416.0k386.0k341.0k383.0k426.0k999.0k855.0k1.2m920.0k1.0m1.0m2.5m2.2m800.0k849.0k614.0k1.5m

Current Assets

21.9m17.5m17.0m12.0m8.7m22.1m19.8m18.6m46.2m39.8m33.4m38.7m35.1m29.2m31.5m25.7m20.5m34.9m30.1m30.0m58.4m69.5m62.6m54.3m48.1m42.5m34.5m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(13.7m)(14.7m)(30.7m)(22.1m)(16.4m)(15.3m)(32.2m)(24.3m)(44.6m)

Depreciation and Amortization

278.0k320.0k346.0k360.0k267.0k382.0k684.0k855.0k698.0k

Accounts Payable

983.0k201.0k(196.0k)335.0k(296.0k)2.4m1.5m4.3m

Cash From Operating Activities

(14.5m)(17.7m)(22.8m)(25.8m)(13.8m)(10.9m)(24.0m)(13.3m)(35.3m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(7.2m)(9.5m)(4.3m)(8.0m)(11.5m)(9.4m)(15.3m)(20.9m)(11.5m)(10.8m)(15.5m)(12.5m)(13.5m)(20.0m)4.8m(2.2m)(8.2m)(5.6m)(11.9m)(19.1m)(10.2m)(3.2m)(13.0m)(13.0m)(22.6m)(34.7m)(15.6m)

Depreciation and Amortization

127.0k202.0k75.0k155.0k236.0k85.0k171.0k257.0k89.0k182.0k272.0k70.0k136.0k201.0k68.0k134.0k248.0k164.0k331.0k508.0k186.0k376.0k573.0k184.0k341.0k508.0k190.0k

Accounts Payable

897.0k919.0k(233.0k)(132.0k)(724.0k)501.0k30.0k(890.0k)(239.0k)11.0k295.0k(678.0k)(769.0k)(529.0k)400.0k900.0k765.0k1.0m(670.0k)(1.0m)2.0m6.3m5.3m1.2m1.2m1.7m

Cash From Operating Activities

(5.8m)(10.0m)(5.4m)(10.4m)(14.0m)(6.1m)(12.5m)(18.3m)(7.3m)(13.4m)(19.7m)1.1m(4.7m)(8.4m)7.3m852.0k(4.6m)(5.4m)(11.1m)(17.9m)(5.7m)(1.3m)(8.8m)(5.5m)(17.0m)(25.2m)(12.1m)
show all
USDQ2, 2011

Financial Leverage

1.8 x
Show all financial metrics

Athersys Operating Metrics

FY, 2016

Patent Applications

170

Patents (US)

21

Patents Issued

200
Show all operating metrics

Athersys Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

Learn more about about our premium products
SecurityScorecard logo

Athersys Online and Social Media Presence

Athersys's Trends

Embed Graph

Athersys News and Updates

June 22, 2020

Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?

NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
March 30, 2020

HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares

Athersys, Inc. (“Athersys”) (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (“Healios”), exercised in full its warrant to purchase shares of Athersys common stock. Healios purchased 4,000,000 shares at a price of $1.76 per share in accordance with the terms of the warrant, rep…
January 15, 2020

Athersys Names Ivor Macleod Chief Financial Officer

Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercial…
June 04, 2019

Athersys to Present at Jefferies 2019 Healthcare Conference

Conference being held June 4-7, 2019 in New York City Conference being held June 4-7, 2019 in New York City
May 28, 2019

Brainstorm Health: Athersys Stem Cell Treatment, Alexa in Medicine, Oklahoma Opioid Suit

Brainstorm Health Daily: May 28, 2019
May 20, 2019

Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference

The MultiStem® treatment group had more ventilator-free and ICU-free days, and greater reduction in acute inflammatory biomarkers compared to the placebo The MultiStem® treatment group had more ventilator-free and ICU-free days, and greater reduction in acute inflammatory biomarkers compared to the …
Show more

Athersys Blogs

October 09, 2018

Athersys Third Quarter 2018 Results Webcast

Athersys Third Quarter 2018 Results Webcast joseibrahim.de… Tue, 10/09/2018 - 14:57 Athersys Third Quarter 2018 Results Webcast Display "add to calendar" true Event Type Earnings Conference Call Event Categories …
September 24, 2018

092418 Cell & Gene Meeting on the Mesa

092418 Cell & Gene Meeting on the Mesa khunady@athersys.com Mon, 09/24/2018 - 10:48 Cell & Gene Meeting on the Mesa Display "add to calendar" true Event Type Conference Presentation Event Categories …
Show more

 Athersys Frequently Asked Questions

  • When was Athersys founded?

    Athersys was founded in 1995.

  • Who are Athersys key executives?

    Athersys's key executives are Gil Van Bokkelen, William Lehmann and John Harrington.

  • How many employees does Athersys have?

    Athersys has 83 employees.

  • What is Athersys revenue?

    Latest Athersys annual revenue is $5.6 m.

  • What is Athersys revenue per employee?

    Latest Athersys revenue per employee is $67.9 k.

  • Who are Athersys competitors?

    Competitors of Athersys include Rani Therapeutics, BeyondSpring and Biogen.

  • Where is Athersys headquarters?

    Athersys headquarters is located at 3201 Carnegie Ave, Cleveland.

  • Where are Athersys offices?

    Athersys has offices in Cleveland and Canton.

  • How many offices does Athersys have?

    Athersys has 2 offices.